MiNK Therapeutics (INKT) Competitors $14.00 -0.55 (-3.78%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$13.75 -0.25 (-1.79%) As of 10/10/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. FTFT, VYGR, RENB, RNAC, TNYA, FHTX, LFCR, PBYI, PRQR, and VORShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Future FinTech Group (FTFT), Voyager Therapeutics (VYGR), Lunai Bioworks (RENB), Cartesian Therapeutics (RNAC), Tenaya Therapeutics (TNYA), Foghorn Therapeutics (FHTX), Lifecore Biomedical (LFCR), Puma Biotechnology (PBYI), ProQR Therapeutics (PRQR), and Vor Biopharma (VOR). MiNK Therapeutics vs. Its Competitors Future FinTech Group Voyager Therapeutics Lunai Bioworks Cartesian Therapeutics Tenaya Therapeutics Foghorn Therapeutics Lifecore Biomedical Puma Biotechnology ProQR Therapeutics Vor Biopharma MiNK Therapeutics (NASDAQ:INKT) and Future FinTech Group (NASDAQ:FTFT) are related small-cap companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings. Which has better valuation & earnings, INKT or FTFT? MiNK Therapeutics has higher earnings, but lower revenue than Future FinTech Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$9.51M-$2.88-4.86Future FinTech Group$2.16M19.50-$32.96MN/AN/A Do analysts prefer INKT or FTFT? MiNK Therapeutics currently has a consensus target price of $37.50, indicating a potential upside of 167.86%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe MiNK Therapeutics is more favorable than Future FinTech Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.33Future FinTech Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media refer more to INKT or FTFT? In the previous week, MiNK Therapeutics and MiNK Therapeutics both had 4 articles in the media. Future FinTech Group's average media sentiment score of 0.72 beat MiNK Therapeutics' score of 0.62 indicating that Future FinTech Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Future FinTech Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, INKT or FTFT? MiNK Therapeutics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Future FinTech Group has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Do institutionals & insiders have more ownership in INKT or FTFT? 2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Future FinTech Group shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by insiders. Comparatively, 0.9% of Future FinTech Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is INKT or FTFT more profitable? MiNK Therapeutics' return on equity of 0.00% beat Future FinTech Group's return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -227.24% Future FinTech Group N/A -347.16%-200.95% SummaryMiNK Therapeutics beats Future FinTech Group on 8 of the 12 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.81M$3.38B$6.11B$10.63BDividend YieldN/A2.29%5.66%4.71%P/E Ratio-4.8621.9785.2726.57Price / SalesN/A462.21612.79132.63Price / CashN/A47.2238.5062.09Price / Book-2.8310.2112.726.53Net Income-$9.51M-$52.40M$3.30B$275.96M7 Day Performance-6.79%0.88%0.95%-0.73%1 Month Performance-4.44%10.41%6.35%3.71%1 Year Performance108.64%27.28%80.42%37.30% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.8374 of 5 stars$14.00-3.8%$37.50+167.9%+106.5%$65.81MN/A-4.8630News CoverageAnalyst ForecastFTFTFuture FinTech Group0.3881 of 5 stars$2.19-1.8%N/A-32.6%$40.97M$2.37M0.0070News CoverageAnalyst ForecastShort Interest ↑VYGRVoyager Therapeutics4.1279 of 5 stars$4.86+3.0%$13.25+172.6%-27.2%$269.58M$80M-2.63100News CoverageAnalyst ForecastRENBLunai Bioworks0.701 of 5 stars$1.54+21.7%N/A-65.0%$265.24MN/A-2.0020Positive NewsGap DownRNACCartesian Therapeutics1.8184 of 5 stars$10.19-1.5%$40.00+292.5%-55.4%$264.94M$38.91M-0.1964News CoverageAnalyst ForecastTNYATenaya Therapeutics2.9595 of 5 stars$1.62+1.3%$6.25+285.8%+28.0%$264.02MN/A-1.69110News CoverageAnalyst ForecastGap UpFHTXFoghorn Therapeutics2.5299 of 5 stars$4.64+2.2%$11.00+137.1%-42.5%$262.30M$22.60M-3.90120News CoverageAnalyst ForecastLFCRLifecore Biomedical1.9533 of 5 stars$6.98-1.1%$8.00+14.6%+44.8%$261.51M$128.87M-5.33690News CoverageAnalyst ForecastPBYIPuma Biotechnology4.0687 of 5 stars$5.13-1.7%$7.00+36.5%+88.9%$258.40M$230.50M5.23200Positive NewsAnalyst UpgradePRQRProQR Therapeutics1.9291 of 5 stars$2.45+8.9%$8.00+226.5%+28.2%$257.77M$20.46M-5.33180News CoveragePositive NewsAnalyst ForecastVORVor BiopharmaN/A$37.46+2.1%$113.83+203.9%N/A$256.75MN/A-22.70140 Related Companies and Tools Related Companies Future FinTech Group Competitors Voyager Therapeutics Competitors Lunai Bioworks Competitors Cartesian Therapeutics Competitors Tenaya Therapeutics Competitors Foghorn Therapeutics Competitors Lifecore Biomedical Competitors Puma Biotechnology Competitors ProQR Therapeutics Competitors Vor Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
